Cargando…
Cilostazol inhibits plasmacytoid dendritic cell activation and antigen presentation
BACKGROUND: Cilostazol, an anti-platelet drug for treating coronary heart disease, has been reported to modulate immune cell functions. Plasmacytoid dendritic cells (pDCs) have been found to participate in the progression of atherosclerosis mainly through interferon α (IFN-α) production. Whether cil...
Autores principales: | Sun, Fei, Yin, Zhao, Yu, Hai-Sheng, Shi, Quan-Xing, Zhao, Bei, Zhang, Li-Guo, Wang, Shou-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Science Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554787/ https://www.ncbi.nlm.nih.gov/pubmed/26345215 http://dx.doi.org/10.11909/j.issn.1671-5411.2015.04.011 |
Ejemplares similares
-
MHC class II–restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell–mediated autoimmunity
por: Irla, Magali, et al.
Publicado: (2010) -
Plasmacytoid Dendritic Cells and Cancer Immunotherapy
por: Fu, Chunmei, et al.
Publicado: (2022) -
Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma
por: Zhang, Xinning, et al.
Publicado: (2022) -
Plasmacytoid Dendritic Cells Capture and Cross-Present Viral Antigens from Influenza-Virus Exposed Cells
por: Lui, Gabrielle, et al.
Publicado: (2009) -
Disease-Associated Plasmacytoid Dendritic Cells
por: Li, Shuang, et al.
Publicado: (2017)